[Clinical effects of K-18 (IgG-melphalan) in hypoplastic leukemia: a case report].
Five cases of hypoplastic acute myelocytic leukemia were treated with an IgG-melphalan conjugate, K-18. Eight tablets of K-18, containing 30 mg per tablet, were given daily. One patient, a 68-year-old female, obtained complete remission with a duration of 1.5 + months. Among the four remaining patients without remission, one showed a decrease in leukemic cells in the peripheral blood. No side effects of K-18 were observed except in one patient, showing a slight increase in serum GOT and GPT levels. Further studies with a large group will be necessary to clarify the effect of this drug on hypoplastic leukemia.
D000284:Administration, Oral; D000368:Aged; D004338:Drug Combinations; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008297:Male; D008558:Melphalan / Q000008:administration & dosage*; D012074:Remission Induction; D013607:Tablets; D005719:gamma-Globulins / Q000008:administration & dosage*
D004338:Drug Combinations; D013607:Tablets; D005719:gamma-Globulins; D008558:Melphalan